Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Merck Says ZOSTAVAX Reduced Incidence Of Shingles By About 70% In Phase 3 Study

4/2/2012 10:00 AM ET

Merck & Co. Inc. (MRK: Quote) said data from the pivotal Phase III study with ZOSTAVAX in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases.

ZOSTAVAX is Merck's vaccine for the prevention of herpes zoster, commonly known as shingles. It is the only shingles vaccine licensed for use in the United States.

In the study, ZOSTAVAX significantly reduced the risk of developing shingles by nearly 70 percent in adults ages 50 to 59, compared with placebo. The results from this study provided the data that supported the U.S. Food and Drug Administration's expanded indication for ZOSTAVAX in March 2011 in this age group.

"The results of this study demonstrate the importance of ZOSTAVAX to help prevent shingles in adults ages 50 to 59. More than 95 percent of adults 50 and older have had chickenpox, putting them at risk for developing shingles," said Myron Levin, one of the study's investigators, and professor of pediatrics and medicine, University of Colorado Denver School of Medicine, Section of Pediatric Infectious Diseases, The Children's Hospital.

Click here to receive FREE breaking news email alerts for Merck & Co Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Justin Moore has been named Humanitarian of the Year by by the Armed Forces Foundation. Moore received the award alongside Big Machine Label Group President/CEO Scott Borchetta for their service and commitment to the morale and welfare of military families through the Crown Royal "Your Hero's Name Here" contest. International Business Machines Corp. said Wednesday after the markets closed that its first quarter profit fell 21% from last year, hurt by lower revenue as well as a hefty workforce rebalancing charge. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Stocks moved sharply higher over the course of the trading day on Wednesday, further offsetting the steep losses posted late last week. The markets benefited from a positive reaction to the latest earnings news as well as remarks by Federal Reserve Chairman Janet Yellen. The major averages saw further upside going into the close, ending the session at their best levels of the day.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.